To analyse individual factors that may contribute to leukemic transformation in vivo, we have developed a murine model of leukemogenesis based on the early hematopoietic precursor cell FL5.12. FL5.12 cells are interleukin-3 (IL-3) dependent for growth, proliferation, and survival. Relative resistance to cell death following IL-3 withdrawal can be conferred by either overexpression of the Bcl-x L apoptotic inhibitor, or constitutive activation of the serine/threonine kinase Akt. The ability of Bcl-x L or a constitutively active myristylated Akt to promote leukemic transformation of FL5.12 cells was compared in athymic nu + /nu + mice. Bcl-x L alone could not promote leukemic transformation, but mice injected with FL5.12 cells overexpressing Bcl-x L and a dominant-negative p53 construct developed leukocytosis and blastic infiltration of lymph nodes, spleen, and liver with features of a highgrade lymphoid malignancy. In contrast to the cells injected into these animals, cell lines derived from the mice were able to proliferate in the absence of IL-3, and were found to have constitutively activated Akt. This constitutive activation was associated with a variety of alterations of the signaling pathway regulating Akt activity, including alterations of PTEN mRNA and protein expression. In addition, some of these leukemic clones demonstrated concurrent constitutive upregulation of ERK activity. A constitutively active Akt construct introduced into FL5.12 cells promoted similar clonal expansion in vivo, with emergence of clonal IL-3-independent proliferation. Bclx L and Akt appeared to function cooperatively in this model, enhancing rapid clonal outgrowth in vivo relative to Akt alone. These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis.
To analyse individual factors that may contribute to leukemic transformation in vivo, we have developed a murine model of leukemogenesis based on the early hematopoietic precursor cell FL5.12. FL5.12 cells are interleukin-3 (IL-3) dependent for growth, proliferation, and survival. Relative resistance to cell death following IL-3 withdrawal can be conferred by either overexpression of the Bcl-x L apoptotic inhibitor, or constitutive activation of the serine/threonine kinase Akt. The ability of Bcl-x L or a constitutively active myristylated Akt to promote leukemic transformation of FL5.12 cells was compared in athymic nu + /nu + mice. Bcl-x L alone could not promote leukemic transformation, but mice injected with FL5.12 cells overexpressing Bcl-x L and a dominant-negative p53 construct developed leukocytosis and blastic infiltration of lymph nodes, spleen, and liver with features of a highgrade lymphoid malignancy. In contrast to the cells injected into these animals, cell lines derived from the mice were able to proliferate in the absence of IL-3, and were found to have constitutively activated Akt. This constitutive activation was associated with a variety of alterations of the signaling pathway regulating Akt activity, including alterations of PTEN mRNA and protein expression. In addition, some of these leukemic clones demonstrated concurrent constitutive upregulation of ERK activity. A constitutively active Akt construct introduced into FL5.12 cells promoted similar clonal expansion in vivo, with emergence of clonal IL-3-independent proliferation. BclIntroduction Leukemic transformation of hematopoietic progenitor cells requires alterations in signaling pathways regulating cell survival, cell proliferation, and lineage-specific differentiation (Weissman et al., 2001) . One approach to defining the genetic alterations required for leukemogenesis has been physical mapping of recurring chromosomal rearrangements associated with particular hematologic malignancies (Rowley, 2000) . Chromosomal analyses coupled with advances in cytogenetic methodology have generated a wealth of information regarding the gross genomic alterations associated with leukemic transformation (Drexler et al., 1995; Veldman et al., 1997; Klein, 2000) . These alterations include chromosomal translocations, inversions, duplications, and deletions. Detailed mapping of the breakpoint sites of these events has identified a number of oncogenes and trumor-suppressor genes that contribute to the pathogenesis of these diseases (Korsmeyer, 1992) .
Physical mapping and chromosome walking techniques to identify the relevant genes within a locus of consistent chromosomal alteration can be problematic. With respect to deletions, once the smallest overlappingdeleted segment has been mapped, definitive identification of candidate oncogenes or tumor-suppressors among the potentially causative genes within the region is often difficult. This task is further complicated by the recent description of a number of tumor-suppressor genes that have a haploinsufficient phenotype: such critical loci would be missed entirely by most physical mapping approaches, as in the hemizygous state the remaining allele retains a wild-type sequence (Barlow et al., 1999; Komuro et al., 1999; Song et al., 1999) . In addition, promoter methylation is increasingly recognized as an important mechanism for tumor-suppressor gene inactivation without alteration of genetic sequence or chromosomal disruption (Issa et al., 1997) .
As an alternative to positional cloning, we have developed a murine model for the functional assessment of genes involved in leukemic transformation using a nontransformed cell line, FL5.12. FL5.12 was derived as an interleukin-3 (IL-3)-dependent cell line from murine fetal liver, and has characteristic features of an early lymphocytic progenitor (McKearn et al., 1985) . Here we demonstrate that FL5.12 cells can be manipulated to identify molecular pathways contributing to leukemia in vivo. In addition to the evaluation of candidate oncogenes, clonal selection of nontransformed hematopoietic progenitor lines in vivo may provide a powerful method with which to screen for novel genes involved in leukemogenesis through random insertional mutagenesis with tagged constructs.
Resistance to apoptotic cell death has been shown to be a key factor in malignant transformation in many model systems (Rudin and ). The Bcl-2 family of apoptotic regulators includes both proapoptotic and antiapoptotic factors, and the relative expression of the various Bcl-2 family members appears to be a central determinant of apoptotic sensitivity (Adams and Cory, 2001 ). Among the Bcl-2 family members, the antiapoptotic factor Bcl-x L has been found to be upregulated in a variety of human cancers, including both solid tumors and leukemias (Xerri et al., 1998; Huang, 2000) . Bcl-x L is localized to several intracellular membranes, including the outer mitochondrial membrane, where it has been implicated in the regulation of a series of mitochondrial alterations associated with apoptotic induction Adams and Cory, 2001 ). In cells treated with an apoptotic stimulus, Bcl-x L can function to maintain mitochondrial membrane potential, facilitate continued mitochondrial bioenergetic function, and prevent mitochondrial swelling and release of cytochrome c from the intermembrane space. Cytoplasmic cytochrome c has been shown to promote the activation of downstream caspases, proteolysis enzymes that cause many of the characteristic morphologic alterations of apoptotic cells.
The serine/threonine kinase Akt has also been implicated in several models of carcinogenesis (Staal, 1987; Datta et al., 1999; Nicholson and Anderson, 2002) . Akt is activated following engagement of cytokine family receptors (including the IL-3 receptor), receptor tyrosine kinases, and G-protein-coupled receptors. Activated receptors recruit and activate Phosphatidylinositol-3 kinase to generate phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ). Among other effects, PIP 3 stimulates the phosphorylation of Akt by phosphoinositide-dependent kinase-1 (PDK-1), leading to Akt activation. PTEN, a tumor suppressor that is inactivated in many human malignancies, functions to suppress PIP 3 levels, inactivating the Akt signaling pathway as well as other PIP 3 -dependent signaling pathways. Akt has a number of downstream targets, and has been implicated in the regulation of apoptotic induction, proliferation, differentiation, and metabolism (Nicholson and Anderson, 2002) . Among the kinase substrates of Akt are IKKa (phosphorylation of which promotes the degradation of I-kB, leading in turn to activation and nuclear translocation of the transcription factor NFkB), members of the Forkhead family of transcription factors (phosphorylation and inactivation of which inhibits transcription of a number of downstream genes encoding proapoptotic factors such as Bim and FasL), and the proapoptotic Bcl-2 family member BAD (phosphorylation of which leads to inactivation and sequestration by 14-3-3 proteins).
Akt also has been shown to promote glycolytic metabolism, potentially through phosphorylation of glycolytic regulators including phosphofructokinase 2, glycogen synthase, and the glucose transporter Glut l (Cross et al., 1997; Barthel et al., 1999) . Growth factor withdrawal has been shown to markedly suppress glycolytic metabolism, and recent data suggest that Akt may in part inhibit apoptosis through maintenance of glycolysis (Gottlob et al., 2001; Plas et al., 2001; Vander Heiden et al., 2001) . In contrast, Bcl-x L has no effect on the suppression of glycolysis following growth factor withdrawal, but may facilitate mitochondrial adaptation to shifts in availability of substrates for oxidative phosphorylation.
Upregulation of both Bcl-x L and Akt activities have been associated with human hematologic malignancies. However, an in vivo analysis of the potential of these genes to promote leukemogenesis has not been performed. Here, we demonstrate that in FL5.12 hematopoietic progenitor cells, in vivo leukemic selection results in constitutive Akt activation, and that constitutive Akt activation can facilitate leukemogenesis. Bcl-x L and Akt may function cooperatively to promote the development of growth-factor-independent proliferation in the malignant transformation of hematopoietic progenitors.
Results
Overexpression of Bcl-x L is not sufficient for leukemic transformation of FL5.12 cells Characteristics of FL5.12-derivative cell lines used in this study are indicated in Table 1 . FL5.12 cells were isolated from a Balb/c murine fetal liver as an IL-3- (Boise et al., 1993) .
To evaluate whether the combination of unlimited proliferative capacity and apoptotic resistance would be sufficient for leukemic transformation in vivo, 10 8 FL5.Bcl-x L cells were introduced by intravenous injection into each of four Balb/c nu + /nu + (athymic) mice. No evidence of morbidity was seen in any of the four recipient mice, observed for a minimum of 6 months postinjection. Peripheral blood samples were taken from these animals 3 months after injection to monitor for persistence of the injected cells. Blood samples were immediately cultured in 10 ml fresh media containing IL-3 and G418. The FL5.Bcl-x L cells injected into these animals were G418-resistant because of the presence of the Bcl-x L expression vector. No G418-resistant cells could be recovered from these animals. Post-mortem examination of spleen and lymph nodes from animals injected with FL5.Bcl-x L cells showed no evidence of lymphocytic expansion, and were histologically indistinguishable from those of control, mock-injected littermates (data not shown).
Overexpression of Bcl-x L together with inactivation of p53 can promote leukemogenesis in vivo In addition to apoptotic inhibition, genomic instability and/or cell cycle dysregulation may be important determinants of malignant transformation (Della Ragione et al., 1995) . To examine the effect of Bcl-x L overexpression coupled with inactivation of p53 on the leukemic potential of FL5.12 cells in vivo, FL5.Bcl-x L cells were transfected with a dominant-negative p53 allele (FL5.x L .DD) (Minn et al., 1996) . Aliquots of 10 8 FL5.x L .DD cells were injected into each of four nude mice. After an average interval of approximately 3 months after injection, all four of these mice developed splenomegaly, lymphadenopathy, and marked leukocytosis (Table 2, cf. Figure 1a , b). G418-resistant subclones derived from the injected cells could be readily cultured from the peripheral blood of these mice.
Peripheral blood smears from animals injected with FL5.x L .DD revealed a predominance of cells demonstrating histologic features suggestive of a high-grade early lymphoid malignancy, including blast forms demonstrating a high nuclear to cytoplasmic ratio, diffuse heterochromatin, and mean cell diameter of 10-12 mm, with a variable content of larger and/or pleomorphic cells (Figure 2b ). Mitotic figures were evident in a range of 2-10 per high-power field. Histologic examination of the grossly enlarged spleens, livers, and inguinal lymph nodes of these animals revealed effacement of the architecture with massive infiltration by blasts resembling those noted in the peripheral blood (Figure 1b) .
The 3-month delay in emergence of the proliferative FL5.x L .DD subclones in mice suggested that the injected cells were not fully competent for proliferative expansion in vivo, but that functional inactivation of p53 in these cells may have facilitated the acquisition of additional growth-promoting alterations. Consistent with this hypothesis, in contrast to the 'parental' FL5.x L .DD cells injected into animals, FL5.x L .DD subclones selected in vivo were consistently found to be capable of proliferation in the absence of the growth factor IL-3 (Figure 3 ).
Selection of FL5.x L .DD subclones in vivo is associated with upregulation of Akt
The emergence of IL-3-independent growth in the FL5.x L .DD cells selected in vivo suggested that the inactivation of p53 in these cells may have facilitated the acquisition of additional mutations affecting IL-3-dependent pathways in these cells. Several downstream signaling pathways are known to be activated by IL-3 receptor engagement, including activation of Akt by PI3K, activation of ERK through the mitogen-activated protein kinase (MAPK) cascade, and activation of the Stat5 signaling protein by Jak2 (Talapatra and ). Activation of each of these signaling pathways was interrogated in the leukemic clones derived from FL5.x L .DD. A consistent upregulation of phosphorylated Akt was observed in the leukemic clones from all four mice, in contrast to the parental FL5.x L .DD cells injected into these mice (Figure 4a ). The level of phospho-Akt in the leukemic clones appeared to be independent of the presence or absence of IL-3. These data suggested that activation of Akt might be an important contributor to leukemic growth in this model.
The constitutive activation of Akt may have derived from independent mutations in the four mice, leading to distinct clonal lines. Alternatively, it was possible that these seemingly independent events in fact represented selection of the same precursor subclone, present at low concentration in the original FL5.x L .DD population injected into these mice. To evaluate this possibility, we examined the PTEN status of the parental and leukemic lines. PTEN loss is a frequent mechanism for constitutive Akt activation in human tumors. Clones 3 and 4 (Downward, 1998) . Constitutive activation of Akt in clones 1 and 2 could be explained by loss of PTEN. To evaluate alternative mechanisms for constitutive Akt activation in clones 3 and 4, we evaluated levels of phosphorylated ERK in these lines (Figure 4b) . The parental FL5.x L .DD cells, as well as clones 1 and 2, demonstrated detectable phospho-ERK in the presence of IL-3, but downregulation of phospho-ERK following IL-3 withdrawal. In contrast, phospho-ERK levels in clones 3 and 4 were markedly higher than in either the parental cells or the other clones, both in the presence and absence of IL-3. This result demonstrated that the constitutive upregulation of Akt activity in clones 3 and 4 was associated with a similarly Genetic determinants of leukemogenesis R Karnauskas et al constitutive upregulation of ERK activity, and further supported that distinct molecular mechanisms are responsible for Akt activation in these leukemic clones.
The constitutive upregulation of phospho-Akt and phospho-ERK in clones 3 and 4 was consistent with aberrant signaling downstream of the IL-3 receptor, or alternatively with expression of a constitutively active receptor. Examination of Stat5 activation in these lines demonstrated similar phosphorylated Stat5 levels in the parental and leukemic lines in the presence of IL-3, and a consistent loss of phosphorylated Stat5 after IL-3 withdrawal (Figure 4c ). This result confirmed that all of these cells retain responsiveness to exogenous IL-3 in some signaling pathways, and suggested that alteration in Stat5-dependent signaling was not responsible for leukemic transformation in this model.
Constitutively active Akt can promote leukemogenesis
The role of Akt in leukemic transformation of FL5.12 cells was further investigated using a constitutively activated, myristylated form of Akt (mAkt) under the control of a doxycycline-inducible promoter. Two independent FL5.12-stable transfectants were investigated, FL5.mAkt2 and FL5.mAkt3. Low-level mAkt expression is detectable in the absence of doxycycline in both FL5.mAkt2 and FL5.mAkt3 cell lines, and both lines demonstrate upregulated mAkt expression in the presence of doxycycline (Figure 6 ). Aliquots of 10 8 FL5.mAkt2 or FL5.mAkt3 cells were injected intravenously into Balb/c athymic mice. Four mice, two injected with FL5.mAkt2 and two injected with FL5.mAkt3, were given drinking water containing only 1% sucrose, while the remaining mice were given water supplemented with 0.5 mg/ml doxycycline with 1% sucrose to induce high-level expression of mAkt. After an average of 62 days, four of four doxycycline-treated mice injected with FL5.mAkt2 and four of eight doxycycline-treated mice injected with FL5.mAkt3 developed grossly evident splenomegaly, lymphadenopathy, and marked leukocytosis (Figure 1c, d and Table 2 ). Peripheral blood smears and tissue histology revealed large pleomorphic peripheral blood blasts, with diffuse organ infiltration and architectural effacement similar to that seen in the mice injected with FL5.x L .DD I (f) cell lines. Blood samples from all injected animals were drawn after development of grossly evident splenomegaly. Peripheral blast count ranges are indicated in Table 1 Genetic determinants of leukemogenesis R Karnauskas et al ( Figure 1c, d and 2c, d ). G418-resistant cells able to proliferate in the absence of IL-3 were recovered from peripheral blood of these animals ( Figure 3 ). In contrast, none of the four mice not given doxycycline and injected with either FL5.mAkt line developed any evidence of leukemia, and no remaining FL5.mAkt cells Genetic determinants of leukemogenesis R Karnauskas et al could be recovered from peripheral blood of these animals after 3-6 months using media with or without IL-3. Akt has been shown to regulate a number of critical apoptotic pathways. If doxycycline, or doxycyclineinduced Akt activity, were markedly increasing the proliferative rate of FL5.mAkt cells, this might offer an alternative explanation for the preferential leukemic growth of these cells in the presence of doxycycline. However, in parental FL5.mAkt2 cells, proliferative rate was actually significantly lower in the presence of doxycycline (Figure 7) . Growth rates of the four derivative leukemic clones of FL5.mAkt2 demonstrated similar proliferative rates to the parental line, with a similar inhibitory effect of doxycycline. These results suggest that the effect of doxycycline exposure on leukemic transformation was not dependent on proliferative induction, and is consistent with the known role of Akt in apoptotic inhibition.
Akt and Bcl-x L can cooperate in leukemogenesis
Only four of eight mice injected with FL5.mAkt3 and given doxycycline developed leukocytosis. We used this line to analyse whether Akt and Bcl-x L could provide synergy in leukemic transformation in vivo. The FL5.mAkt3 line was transfected with a vector-driving expression of Bcl-x L , and a clone with stable Bcl-x L expression was selected (FL5.mAkt3.x L ). Aliquots of 10 8 FL5.mAkt3.x L cells were administered by intravenous injection to six Balb/c athymic mice, four of which were given doxycycline in their drinking water. All four mice treated with doxycycline developed massive splenomegaly, leukocytosis, and lymphadenopathy, grossly evident after a median of 46 days (Figures 1e, and 2e , Table 2 ). The interval to development of palpable splenomegaly in these animals was significantly shorter than that of the mice injected with FL5.mAkt cells (Figure 8a ; P ¼ 0.0005 by log-rank test). Interestingly, in (Figure 6 ). Histologic evaluation of the grossly infiltrated liver, spleen, and lymph nodes in these animals revealed a similar pattern of organ effacement with infiltrating pleomorphic blasts to that noted in the FL5.x L .DD-and FL5.mAkt-injected mice. The relatively rapid interval between injection and leukemic outgrowth in mice injected with FL5.mAkt3.x L when compared to FL5.mAkt is consistent with a cooperativity between Akt and Bcl-x L in cellular transformation. The development of clonal leukemic growth in the absence of doxycycline in animals injected with FL5.mAkt3.x L (but not with either FL5.mAkt line) further supports a synergistic interaction between Akt and Bcl-x L .
IL-3-independent proliferation is an important contributor to leukemogenesis in vivo
The emergence of IL-3-independent subclones from mice injected with IL-3-dependent FL5.x L .DD, FL5.mAkt, and FL5.mAkt.x L cells suggested that growth factor independence was a major determinant of proliferative capacity in vivo. To test this hypothesis directly, FL5.Bcl-x L cells were repeatedly withdrawn from IL-3 in culture, to derive a subclone that was IL-3-independent for growth in vitro (repeated attempts to generate an IL-3-independent FL5.12 derivative without Bcl-x L were unsuccessful; data not shown). Aliquots of 10 8 cells per mouse of the resultant cell line, FL5.x L .IL3 I , were injected into eight athymic recipient mice. All of these animals developed splenomegaly, lymphadenopathy, and marked leukocytosis within 13-16 days after injection (Figure 8b ). Histologic evaluation of the organs and peripheral blood from these animals revealed a similar diffuse infiltration of early blast forms to that seen in the other FL5.12 derivative lines described above (Figures 1f and 2f) .
Discussion
Proliferation and survival of FL5.12 cells are dependent on the continued presence of the growth factor IL-3. Evolution of a leukemic phenotype in vivo requires an acquisition of growth factor independence. Our results Akt and Bcl-x L may promote leukemogenesis through distinct biologic response pathways. Cell growth is a prerequisite for cell proliferation, and Akt is a critical regulator of both cellular growth and survival (Lawlor and Alessi, 2001) . Akt gene amplification and inactivation of the tumor-suppressor PTEN leading to constitutive Akt activation are frequent events associated with malignant progression (Bellacosa et al., 1993; Cheng et al., 1996; Datta et al., 1999) . Akt has been shown to promote continued cell growth and metabolism in cells under conditions of relative growth-factor deprivation by increasing glucose uptake and glycolysis (Gottlob et al., 2001; Plas et al., 2001; Vander Heiden et al., 2001) .
In contrast to Akt, Bcl-x L does not appear to modulate glucose uptake or metabolism, and does not have growth-promoting effects Plas and Thompson, 2002) . Bcl-x L inhibits apoptotic cell death in response to multiple cellular stresses, including growth factor withdrawal and nutrient deprivation. Bclx L appears to facilitate cellular and mitochondrial adaptation to decreases in growth factor or nutrient availability independent of any effects on glycolytic metabolism.
Although both Bcl-x L and Akt increase cell survival following growth factor withdrawal, FL5.12 cells expressing either Bcl-x L or activated Akt remain dependent on IL-3 for proliferation in vitro. The activities of these genes can be clearly differentiated in vivo. In this experimental system, Bcl-x L is more potent than the activated Akt gene as an inhibitor of cell death following growth factor withdrawal ). Nevertheless, expression of an activated Akt was sufficient to promote evolution of IL-3 independent leukemic subclones in vivo, whereas overexpression of Bcl-x L did not lead to development of such clones unless Bcl-x L overexpression was coupled with a second genetic alteration promoting cell growth or cell cycle dysregulation (i.e. mAkt or p53-DD). These data indicate the importance of the growth promoting effects of Akt in tumorigenesis, and suggest an explanation for the frequent dysregulation of the PI3K-Akt pathway in both hematologic and solid malignancies.
Our data demonstrate that constitutive activity of Akt can facilitate the development of IL-3 independence and leukemogenesis in vivo. However, Akt activation alone is not sufficient to explain the development of IL-3-independent proliferation. Approaches to defining other molecular defects that can contribute to growth-factor independence and leukemic transformation in this model include a candidate gene approach, investigating known oncogenic signaling pathways, and the use of traceable retroviral tags for random insertional mutagenesis (Lund et al., 2002) . The latter approach may prove to be a particularly powerful means of identifying genes contributing to cellular transformation in this leukemic model.
Materials and methods

Derivation of cell lines
The stable transfectant of FL5.12 with pSFFV-Bcl-x L (FL5. Bcl-x L ) has been previously described (Boise et al., 1993) . The FL5.x L .DD cell line, containing the Bcl-x L gene and a dominant-negative p53 allele, was derived from FL5.12 cells transfected with pSFFV-Bcl-x L and pCMVDD (Shaulian, 1992) , and has been shown to be functionally deficient in p53 activity, in contrast to the parental line (Minn et al., 1996) . The generation of FL5.mAkt2 and FL5.mAkt3 has been previously described : the myristylated Akt was cloned in the doxycycline inducible vector pRevTRE (Clontech). For generation of FL5.mAkt3.x L , the human Bcl-x L cDNA was cloned into the EcoRI site of the pBabePuro vector, and transfected into FL5.mAkt3 by electroporation (960 mF, 250 V). Stable transfectants were selected in 1 mg/ml puromycin (Sigma), cloned by limiting dilution, and individual clones screened for Bcl-x L expression by Western blot as previously described (Minn et al., 1999) . FL5.x L .IL.3 I was generated from FL5.Bcl-x L cells by repeated IL-3 withdrawal. FL5.Bcl-x L cells grown with IL-3 were washed three times in phosphatebuffered saline (PBS) and incubated at 10 4 cells/ml in media lacking IL-3 for 7 days. Surviving cells were grown for 4 days in the presence of IL-3, and IL-3 withdrawal was repeated. After 3 rounds of IL-3 withdrawal, a subclone was derived that was able to proliferate in media lacking IL-3 (FL5.x L .IL3 I ). To isolate subclones from mice injected with FL5.Bcl-x L , FL5.x L .DD, or FL5.mAkt cell lines, approximately 10 ml blood was placed in media containing 1 mg/ml G418.
Cell culture
FL5.12-derivative lines were cultured as described previously (Vander Heiden et al., 1997) using media containing 1 mg/ml G418. IL-3 is provided in these media by inclusion of 10% WEHI-3B-conditioned media. Media used for evaluation of proliferation in the absence of IL-3 were identical except for the absence of WEHI-3B-conditioned media.
Intravenous administration of cell lines and in vivo monitoring
Cells for injection into mice were grown to a concentration of up to 10 6 cells/ml, washed in PBS, and resuspended at a concentration of 5 Â 10 8 cells/ml in PBS. Aliquots of 200 ml containing 10 8 cells were administered intravenously to anesthetized Balb/c nu + /nu + mice (Jackson) by retro-orbital venous sinus injection. Where indicated, drinking water was supplemented with 1% sucrose with or without 0.5 mg/ml doxycycline (Sigma). For these animals, water was replaced every 7 days in foil-covered water bottles. Mice were monitored for signs of illness by periodic blood sampling and physical examination for palpable inguinal lymphadenopathy and/or hepatosplenomegaly.
Histologic assessment
Approximately 200 ml of blood was withdrawn from the retroorbital sinus of control mice or mice injected with FL5.12-derivative lines prior to euthanasia. Peripheral blood smears were prepared and stained with Modified Wright-Giemsa stain (Protocol Co., HEMA 3) using standard techniques. A complete blood count and differential count was performed on each sample. Spleens, inguinal lymph nodes, and livers from each animal were fixed in 1% formalin, and embedded in paraffin for tissue sectioning. Tissue sections (10 mm) were stained with hematoxylin and eosin.
Western blot analysis
Whole-cell lysates were prepared from 3 Â 10 7 cells, lysed in 300 ml RIPA buffer (Boehringer Mannheim) supplemented with Protease Inhibitor Cocktail (Sigma). Total protein concentration was determined by Bradford assay (Bio-Rad). For Western blots, 50 mg total protein was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto an Immobilon-P membrane (Millipore Corp.). Immunoblotting was conducted using an antiphospho-Ser473-Akt antibody, antiphospho-Tyr694-Stat5, antiphospho-Tyr202/204-p42/44 ERK, or anti-PTEN antibodies (all from Cell Signaling) and visualized with ECL (Amersham Pharmacia Biotech). Membranes were then incubated in stripping buffer (100 mm b-mercaptoethanol, 2% SDS, 62.5 mm Tris-HCl, pH 6.7) for 30 min at 501C and washed twice in PBS + 0.1% Tween. Membranes were blocked and reprobed using anti-Akt (Cell Signaling), antiStat5 (Santa Cruz Biotech), or anti-ERK antibodies (Cell Signaling). Membranes were stripped and reprobed with an bactin antibody (Sigma, C-11). Membrane blocking and all antibody incubations were performed in 5% milk and 0.1% Tween.
Northern blot analysis
RNA was isolated using the High Pure RNA Isolation Kit (Roche). 10 mg Total RNA (10 mg) was loaded onto a 1.2% agarose gel and blotted onto nitrocellulose. Blot was hybridized using a 32 P-labeled probe complementary to the fulllength PTEN cDNA. The probe was derived by RT-PCR of total cellular RNA using primers 5 0 -CAGACATGACAGC-CATCATCAAAGAGATCG, and 5 0 -TCAGACTTTTG-TAATTTGTGAATGCTGATCTTC. Probe was synthesized using the Megaprime DNA labeling system (Amersham). The blot was stripped in a 0.5% SDS solution for 10 min at 1001C and reprobed with a murine anti-b-actin probe.
Analysis of IL-3 independence
Cells were washed 6 times in PBS, and incubated in media without IL-3 at a concentration of 10 5 cells/ml. To induce myristylated Akt in mAkt cell lines, doxycycline was added to the media at a concentration of 1 mg/ml 18 h before IL-3 withdrawal. Cell counts were taken every 24 h, with frequent passage of cells to maintain a density between 10 5 and 10 6 cells/ ml.
